Dr. Jasper Guido van den Boorn

Dr. Jasper Guido van den Boorn Dr. Jasper Guido van den Boorn Curriculum Vitae
A.) General information Name: Adress: Dr. Jasper Guido van den Boorn Institut für Klinische Chemie und Klinische Pharmakologie Biomedizinisches Zentrum (Geb. 344) 1.OG, Raum 020 Sigmund-‐Freud-‐Strasse 25 53127 Bonn Phone: Desk: 0228-‐287-‐51143 Lab: 0228-‐287-‐51162 Email: jvdboorn@uni-‐bonn.de Birthday: 12.08.1980 Nationality: Dutch B.) Scientific career Education: Jan 2005 – Jul 2010 Sep 2002 – Aug 2004 Aug 1999 – Aug 2002 Aug 1993 – May 1999 Doctorate research project, completed with public defense of dissertation. Research performed at the Department of Dermatology and the Netherlands Institute of Pigment Disorders, Academic Medical Center of the University of Amsterdam (UvA), The Netherlands (Dr.). Master program Oncology at the Free University of Amsterdam (MSc. in Oncology). Bachelor program Biomedical Sciences at the Free University of Amsterdam (BSc. in Biomedical Sciences). Gymnasium (β) at the Rijnlands Lyceum in Oegstgeest. Dr. Jasper Guido van den Boorn Research experience: Jan 2011 – present Junior research group leader on cellular immunity and innate immune activation, Dept. of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany (Lab of Prof. G. Hartmann). Jan 2011 – present Team member biotech start-‐up ‘Rigontec’ GmbH i.G. (Prof. G. Hartmann CEO a.i.); proof-‐of-‐concept & pharmacodynamics. Jul 2010 – Dec 2010 Postdoc on melanoma immunotherapy, at the Lab. of Exp. Dermatology of the Academic Medical Center of the University of Amsterdam (Lab of dr. R.M Luiten, prof. J.D. Bos and prof. C.J.M. Melief). Jan 2005 – Jul 2010 PhD research project: “Vitiligo pathogenesis and immunotherapy of melanoma”. Lab. Of Exp. Dermatology of the Academic Medical Center of the University of Amsterdam (co-‐promotor: dr. R.M Luiten, promotores: prof. J.D. Bos and prof. C.J.M. Melief). Awards 2011 Scientific Outreach Award (University of Amsterdam) Research Funding Dec 2012 Bayer Cooperation Grant (3 years). March 2011 BONFOR research grant (2 years). Professional memberships •
Association for Cancer Immunotherapy (CIMT) •
International Society for Extracellular Vesicles (ISEV) •
Dutch Society for Immunology (NVVI) C.) Publications Key publications in peer-‐reviewed journals 1. J.G. van den Boorn and Gunther Hartmann. Turning tumors into vaccines: co-‐opting the innate immune system. Immunity. 2013, 25;39(1):27-‐37. 2. J.G. van den Boorn, Juliane Daßler, Christoph Coch, Martin Schlee, Gunther Hartmann. Exosomes as nucleic acid nanocarriers. Advanced Drug Delivery Reviews. 2013, 65(3): 331-‐335. 3. J.G. van den Boorn, M. Schlee, C. Coch and G. Hartmann. SiRNA delivery with exosome nanoparticles. Nature Biotechnology, 2011, 29(4):325-‐326. Dr. Jasper Guido van den Boorn 4. J.G. van den Boorn, D.I. Picavet, P.F. van Swieten et al. Skin-‐depigmenting agent monobenzone induces potent T cell autoimmunity towards pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol, 2011, 131:1240. Featured in ‘Commentaries’ section: J Invest Dermatol, 2011, 131:1185. Featured in ‘Clinical Snippets’ section: J Invest Dermatol, 2011, 131: 1178. Featured as full-‐cover illustration on issue J Invest Dermatol, 2011, 131. 5. J.G. van den Boorn, D. Konijnenberg, W. Douwenga et al. Effective melanoma immunotherapy in mice by the skin-‐depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One, 2010, 13;5(5):e10626 6. J.G. van den Boorn, D. Konijnenberg, T.A. Dellemijn et al. Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. J Invest Dermatol, 2009, 129: 2220-‐2232. Featured in ‘Clinical Snippets’ section: J Invest Dermatol, 2009, 129:2081. Stand: 04/2014

Download Report